Brexit would irreparably damage UK pharma industry
A Brexit in the upcoming EU referendum could directly damage the UK pharmaceutical industry, according to NonStop Recruitment.
An analysis by the specialist pharmaceutical and life sciences recruitment consultancy found that the UK leaving the EU would mean the sector would still have to follow regulations to sell in the single market, but that it would have no say over what these regulations were. It would also mean the UK would lose out on the greater patent protection and support for research that it currently gains from being a member state, as well as the expertise of thousands of highly skilled professionals.
Matt Beedle, Team Leader within NonStop Pharma comments: “From our analysis and the many others that have been released it’s clear that the pharmaceutical and life sciences fields would be directly impacted in the case of a Brexit. Yes, the situation isn’t perfect at the moment however, the outlook would still be far worse if we were to vote leave. In this instance there’s a high chance that the EMA (European Medicines Agency) would relocate and therefore many of the pharma companies headquartered in the UK could leave – potentially to Ireland. This is because one of the major reasons many pharma firms have their headquarters in the UK is due to the proximity of the London-based EMA. In addition we’d still need to trade in the single market, however we would no longer have any say in what regulations we would be following, which would obviously damage our competitiveness and would likely weaken our position significantly. The sector would also struggle to keep hold of the thousands of European professionals who currently provide expertise to firms on these shores. We have such a powerful industry here that it seems like a huge error to leave, particularly at a time when our industrial output is growing at its fastest rate for four years, which has been heavily boosted by the pharma sector.”
“For NonStop as a business a leave vote would be particularly unwelcome. We place a big focus on providing the best possible working environment, part of which involves allowing our employees to work in any of our offices across Europe. A Brexit would mean we would face a much larger administrative burden to continue having a diverse workforce, something which we know directly contributes to our success as a business. And it’s not just us that would be affected, the knock on effects would impact all UK businesses that utilise the expertise of European professionals.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.